Thomas Riera

Thomas Riera is a seasoned professional in drug discovery, currently serving as Director of Lead Discovery at Ipsen since August 2022. This role followed the Ipsen acquisition of Epizyme, where Riera held both Director and Associate Director positions from July 2013 to August 2022, focusing on epigenetic target-based drug discovery in oncology. Prior to Epizyme, Riera gained experience at Sirtris, a division of GSK, where leadership roles included Associate Director and Senior Scientist, with a focus on sirtuin enzymes. Riera's career began at Cubist Pharmaceuticals, contributing to high-throughput screening, and included research technician roles at Amira Pharmaceuticals. Riera holds a Ph.D. in Biochemistry from Brandeis University and a B.S. in Physiology & Neurobiology from the University of Connecticut.